IDEXX Laboratories Inc
NASDAQ:IDXX

Watchlist Manager
IDEXX Laboratories Inc Logo
IDEXX Laboratories Inc
NASDAQ:IDXX
Watchlist
Price: 543.45 USD 0.46% Market Closed
Updated: May 20, 2024

Net Margin
IDEXX Laboratories Inc

23.3%
Current
22%
Average
2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.3%
=
Net Income
866.5m
/
Revenue
3.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45B USD
23%
US
Abbott Laboratories
NYSE:ABT
181.1B USD
14%
US
Intuitive Surgical Inc
NASDAQ:ISRG
141.5B USD
27%
US
Stryker Corp
NYSE:SYK
127.5B USD
16%
IE
Medtronic PLC
NYSE:MDT
114.2B USD
13%
US
Boston Scientific Corp
NYSE:BSX
109.7B USD
12%
US
Becton Dickinson and Co
NYSE:BDX
68.6B USD
7%
DE
Siemens Healthineers AG
XETRA:SHL
59.2B EUR
8%
US
Edwards Lifesciences Corp
NYSE:EW
53.7B USD
23%
US
Dexcom Inc
NASDAQ:DXCM
52B USD
17%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
373.7B CNY
34%
IDEXX Laboratories Inc
NASDAQ:IDXX
Country US
Market Cap 45B USD
Net Margin
23%
Abbott Laboratories
NYSE:ABT
Country US
Market Cap 181.1B USD
Net Margin
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Country US
Market Cap 141.5B USD
Net Margin
27%
Stryker Corp
NYSE:SYK
Country US
Market Cap 127.5B USD
Net Margin
16%
Medtronic PLC
NYSE:MDT
Country IE
Market Cap 114.2B USD
Net Margin
13%
Boston Scientific Corp
NYSE:BSX
Country US
Market Cap 109.7B USD
Net Margin
12%
Becton Dickinson and Co
NYSE:BDX
Country US
Market Cap 68.6B USD
Net Margin
7%
Siemens Healthineers AG
XETRA:SHL
Country DE
Market Cap 59.2B EUR
Net Margin
8%
Edwards Lifesciences Corp
NYSE:EW
Country US
Market Cap 53.7B USD
Net Margin
23%
Dexcom Inc
NASDAQ:DXCM
Country US
Market Cap 52B USD
Net Margin
17%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Country CN
Market Cap 373.7B CNY
Net Margin
34%

Profitability Report

View the profitability report to see the full profitability analysis for IDEXX Laboratories Inc.

Full Profitability Report

See Also

Summary
IDXX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IDXX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IDXX stock valuation using valuation multiples.
Wall Street Estimates
IDXX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IDXX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.3%
=
Net Income
866.5m
/
Revenue
3.7B
What is the Net Margin of IDEXX Laboratories Inc?

Based on IDEXX Laboratories Inc's most recent financial statements, the company has Net Margin of 23.3%.

ALPHA SPREAD
Join more than 138,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.